ABM's leadership changes underscore its growth focus and commitment to team building via internal advancement and external recruitment. The new appointments are anticipated to fuel future growth in their respective segments and across the company.
ABM Industries' low P/E ratio is due to predicted earnings drop. Shareholders accept this, acknowledging future earnings may not surprise positively. Hence, a significant share price rise seems unlikely soon.
Despite satisfactory EPS growth over the past half-decade, the market appears relatively pessimistic due to the minor increase in share price. The relatively low P/E ratio (11.34) could also be an indicator of this market apprehension.
ABM's favorable long-term growth trend and a history of consistent dividends make it an appealing investment option, notwithstanding muted 2024 forecasts. ABM's ELEVATE strategy also shows promise, underscoring its potential beyond surface level projections.
$特斯拉(TSLA.US)$— Shares fell 1.2% after U.S. safety regulators said Tesla will recall more than 2 million vehicles to fix issues with its driver assistance system. The electric vehicle maker will send out a software update to fix the problem, which impacts models Y, S, 3 and X produced between Oct. 5, 2012 and Dec. 7, 2023. $輝瑞(PFE.US)$— The biopharmaceutical stock dropped 7.4% after Pfizer issued full-year guidance for adjusted earnings ...
Pre-Market Stock Movers Gapping up $Adobe(ADBE.US)$stock rose 1.6% after Mizuho Securities upgraded the computer software company to ‘buy’ from ‘neutral’, saying it is well-positioned to capitalize on digital transformation with its highly comprehensive end-to-end offering. $DocuSign(DOCU.US)$stock rose 1% after the e-signature company beat expectations in its second quarter, with revenue up 10.5% year-on-year, and thu...
Gapping up $達美航空(DAL.US)$3.8% (the airline raised its current quarter forecast and issued an upbeat 2023 outlook, citing robust travel demand.) $Moderna(MRNA.US)$+1.6% (The Tuesday advance followed a successful study of a skin cancer treatment involving an experimental Moderna vaccine in combination with$默沙東(MRK.US)$cancer drug Keytruda. $Aspen Group(ASPU.US)$+14.8% (the online education company reported better-...
反導工業股票討論區
Stocks to watch for December 14
Stocks making the biggest moves before the bell:
$輝瑞(PFE.US)$ — The biopharmaceutical stock dropped 7.4% after Pfizer issued full-year guidance for adjusted earnings ...
專欄Today's Pre-Market Stock Movers and Top Ratings: ADBE, RH, GS, GILD and More
Gapping up
$Adobe(ADBE.US)$ stock rose 1.6% after Mizuho Securities upgraded the computer software company to ‘buy’ from ‘neutral’, saying it is well-positioned to capitalize on digital transformation with its highly comprehensive end-to-end offering.
$DocuSign(DOCU.US)$ stock rose 1% after the e-signature company beat expectations in its second quarter, with revenue up 10.5% year-on-year, and thu...
2023前兩季度營收增長3.7%,營業利潤下滑9.4%,淨利潤下滑27.6%。前兩季度的利息費用佔營業利潤的25%,負擔已經很重了。
目前市盈率13.3,市盈率TTM升高到15.5,暫時吸引力不大。
專欄Today's Pre-Market Stock Movers: DAL, MRNA, BBY, ASPU and More
$達美航空(DAL.US)$ 3.8% (the airline raised its current quarter forecast and issued an upbeat 2023 outlook, citing robust travel demand.)
$Moderna(MRNA.US)$ +1.6% (The Tuesday advance followed a successful study of a skin cancer treatment involving an experimental Moderna vaccine in combination with $默沙東(MRK.US)$ cancer drug Keytruda.
$Aspen Group(ASPU.US)$ +14.8% (the online education company reported better-...
暫無評論